Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects

verfasst von: Hongyu Zhao, Weisong Cai, Shitao Su, Debao Zhi, Jie Lu, Shuo Liu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Many studies have investigated the association between the allergic conditions and the risk of glioma. However, the evidence is inadequate to draw robust conclusions because most studies were generally small and conducted in heterogeneous populations. To shed light on these inconclusive findings, we conducted a meta-analysis of studies relating the allergic conditions to the risk of glioma. We identified the relevant studies by searching ISI Web of Science, PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) databases, and Wanfang database by October 2013. We included studies that reported odds ratio (OR) or hazard ratio (HR) with its 95 % confidence interval (CI) for the association between the allergic condition and the risk of glioma. Eighteen independent publications, with 9,986 glioma cases and 118,950 controls, were included. Our results showed that allergic condition was reversely associated with the risk of glioma (OR = 0.78, 95 % CI 0.73–0.83, P < 0.001). The results of our meta-analysis indicated that allergic conditions significantly reduce the risk of glioma.
Literatur
1.
Zurück zum Zitat Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998;88:1–10.PubMedCrossRef Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998;88:1–10.PubMedCrossRef
2.
Zurück zum Zitat Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg. 2003;99:458–66.PubMedCrossRef Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973–1997. J Neurosurg. 2003;99:458–66.PubMedCrossRef
3.
Zurück zum Zitat Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA. 2005;293:615–7.PubMedCrossRef Fisher PG, Buffler PA. Malignant gliomas in 2005: where to GO from here? JAMA. 2005;293:615–7.PubMedCrossRef
4.
Zurück zum Zitat Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRef Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRef
5.
Zurück zum Zitat Fischer U, Rheinheimer S, Krempler A, Löbrich M, Meese E. Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation. Int J Oncol. 2013;43(1):50–6.PubMedCentralPubMed Fischer U, Rheinheimer S, Krempler A, Löbrich M, Meese E. Glioma-amplified sequence KUB3 influences double-strand break repair after ionizing radiation. Int J Oncol. 2013;43(1):50–6.PubMedCentralPubMed
6.
Zurück zum Zitat Kim RK, Suh Y, Cui YH, Hwang E, Lim EJ, Yoo KC, et al. Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells. Cancer Sci. 2013;104(9):1172–7.PubMedCrossRef Kim RK, Suh Y, Cui YH, Hwang E, Lim EJ, Yoo KC, et al. Fractionated radiation-induced nitric oxide promotes expansion of glioma stem-like cells. Cancer Sci. 2013;104(9):1172–7.PubMedCrossRef
7.
Zurück zum Zitat Fan S, Zhao Y, Li X, Du Y, Wang J, Song X, et al. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population. Exp Biol Med (Maywood). 2013;238(9):1075–81.CrossRef Fan S, Zhao Y, Li X, Du Y, Wang J, Song X, et al. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population. Exp Biol Med (Maywood). 2013;238(9):1075–81.CrossRef
8.
Zurück zum Zitat Zhao B, Ye J, Li B, Ma Q, Su G, Han R. DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis. Int J Clin Exp Med. 2013;6(6):438–43.PubMedCentralPubMed Zhao B, Ye J, Li B, Ma Q, Su G, Han R. DNA repair gene XRCC3 Thr241Met polymorphism and glioma risk: a meta-analysis. Int J Clin Exp Med. 2013;6(6):438–43.PubMedCentralPubMed
9.
Zurück zum Zitat Jiang J, Quan XF, Zhang L, Wang YC. The XRCC3 Thr241Met polymorphism influences glioma risk — a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3169–73.PubMedCrossRef Jiang J, Quan XF, Zhang L, Wang YC. The XRCC3 Thr241Met polymorphism influences glioma risk — a meta-analysis. Asian Pac J Cancer Prev. 2013;14(5):3169–73.PubMedCrossRef
10.
Zurück zum Zitat Enciso-Mora V, Hosking FJ, Di Stefano AL, et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer. 2013;108(10):2178–85.PubMedCrossRef Enciso-Mora V, Hosking FJ, Di Stefano AL, et al. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. Br J Cancer. 2013;108(10):2178–85.PubMedCrossRef
11.
Zurück zum Zitat Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol. 1990;8:55–60.PubMedCrossRef Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol. 1990;8:55–60.PubMedCrossRef
12.
Zurück zum Zitat Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Int J Cancer. 1992;51:20–7.PubMedCrossRef Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumors of the brain and meninges: results from the Adelaide Adult Brain Tumor Study. Int J Cancer. 1992;51:20–7.PubMedCrossRef
13.
Zurück zum Zitat Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors and the development of brain tumors. Cancer. 1992;69:2541–7.PubMedCrossRef Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahrendorf J. Medical risk factors and the development of brain tumors. Cancer. 1992;69:2541–7.PubMedCrossRef
14.
Zurück zum Zitat Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer. 1997;71:203–7.PubMedCrossRef Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer. 1997;71:203–7.PubMedCrossRef
15.
Zurück zum Zitat Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumor study. Int J Cancer. 1999;82:155–60.PubMedCrossRef Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumor study. Int J Cancer. 1999;82:155–60.PubMedCrossRef
16.
Zurück zum Zitat Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer. 2002;98:609–15.PubMedCrossRef Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer. 2002;98:609–15.PubMedCrossRef
17.
Zurück zum Zitat Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106:423–8.PubMedCrossRef Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106:423–8.PubMedCrossRef
18.
Zurück zum Zitat Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR. History of allergies and risk of glioma in adults. Int J Cancer. 2006;119:2165–72.PubMedCrossRef Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van Tongeren M, Muir KR. History of allergies and risk of glioma in adults. Int J Cancer. 2006;119:2165–72.PubMedCrossRef
19.
Zurück zum Zitat Schwartzbaum JA, Ahlbom A, Lonn S, et al. An international case–control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2448–54.PubMedCrossRef Schwartzbaum JA, Ahlbom A, Lonn S, et al. An international case–control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007;16:2448–54.PubMedCrossRef
20.
Zurück zum Zitat Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941–50.PubMedCrossRef Wigertz A, Lonn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941–50.PubMedCrossRef
21.
Zurück zum Zitat Scheurer ME, El-Zein R, Thompson PA, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–81.PubMedCrossRef Scheurer ME, El-Zein R, Thompson PA, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–81.PubMedCrossRef
22.
Zurück zum Zitat Berg-Beckhoff G, Schuz J, Blettner M, et al. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur J Epidemiol. 2009;24:433–40.PubMedCrossRef Berg-Beckhoff G, Schuz J, Blettner M, et al. History of allergic disease and epilepsy and risk of glioma and meningioma (INTERPHONE study group, Germany). Eur J Epidemiol. 2009;24:433–40.PubMedCrossRef
23.
Zurück zum Zitat Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009;125:680–7.PubMedCentralPubMedCrossRef Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009;125:680–7.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Lachance DH, Yang P, Johnson DR, et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Am J Epidemiol. 2011;174(5):574–81.PubMedCentralPubMedCrossRef Lachance DH, Yang P, Johnson DR, et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Am J Epidemiol. 2011;174(5):574–81.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev. 2011;20(2):370–8.PubMedCentralPubMedCrossRef McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev. 2011;20(2):370–8.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Lee ST, Bracci P, Zhou M, Rice T, Wiencke J, Wrensch M, et al. Interaction of allergy history and antibodies to specific varicella–zoster virus proteins on glioma risk. Int J Cancer. 2013. doi:10.1002/ijc.28535. Lee ST, Bracci P, Zhou M, Rice T, Wiencke J, Wrensch M, et al. Interaction of allergy history and antibodies to specific varicella–zoster virus proteins on glioma risk. Int J Cancer. 2013. doi:10.​1002/​ijc.​28535.
27.
Zurück zum Zitat Safaeian M, Rajaraman P, Hartge P, Yeager M, Linet M, Butler MA, et al. Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk. Cancer Causes Control. 2013;24(10):1885–91.PubMedCrossRef Safaeian M, Rajaraman P, Hartge P, Yeager M, Linet M, Butler MA, et al. Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk. Cancer Causes Control. 2013;24(10):1885–91.PubMedCrossRef
28.
Zurück zum Zitat Turner MC, Krewski D, Armstrong BK, Chetrit A, Giles GG, Hours M, et al. Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand. Cancer Causes Control. 2013;24(5):949–60.PubMedCrossRef Turner MC, Krewski D, Armstrong BK, Chetrit A, Giles GG, Hours M, et al. Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand. Cancer Causes Control. 2013;24(5):949–60.PubMedCrossRef
29.
Zurück zum Zitat Schwartzbaum J, Ding B, Johannesen TB, Osnes LT, Karavodin L, Ahlbom A, et al. Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst. 2012;104(16):1251–9.PubMedCentralPubMedCrossRef Schwartzbaum J, Ding B, Johannesen TB, Osnes LT, Karavodin L, Ahlbom A, et al. Association between prediagnostic IgE levels and risk of glioma. J Natl Cancer Inst. 2012;104(16):1251–9.PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61(9):1493–510.PubMedCrossRef Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61(9):1493–510.PubMedCrossRef
31.
Zurück zum Zitat Lin Y, Jin Q, Zhang GZ, Wang YJ, Jiang T, Wu AH, et al. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma. Chin Med J (Engl). 2011;124(19):3042–8. Lin Y, Jin Q, Zhang GZ, Wang YJ, Jiang T, Wu AH, et al. Increase of plasma IgE during treatment correlates with better outcome of patients with glioblastoma. Chin Med J (Engl). 2011;124(19):3042–8.
32.
Zurück zum Zitat Calboli FC, Cox DG, Buring JE, Gaziano JM, Ma J, Stampfer M, et al. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst. 2011;103(21):1588–95.PubMedCentralPubMedCrossRef Calboli FC, Cox DG, Buring JE, Gaziano JM, Ma J, Stampfer M, et al. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies. J Natl Cancer Inst. 2011;103(21):1588–95.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Schlehofer B, Siegmund B, Linseisen J, et al. Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy. 2011;66(11):1434–41.PubMedCrossRef Schlehofer B, Siegmund B, Linseisen J, et al. Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy. 2011;66(11):1434–41.PubMedCrossRef
34.
Zurück zum Zitat Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, et al. Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer. 2011;129(8):1932–9.PubMedCentralPubMedCrossRef Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, et al. Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. Int J Cancer. 2011;129(8):1932–9.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Scheurer ME, Amirian E, Cao Y, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 2008;14:6640–6.PubMedCentralPubMedCrossRef Scheurer ME, Amirian E, Cao Y, et al. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 2008;14:6640–6.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, et al. Allergy and risk of glioma: a meta-analysis. Eur J Neurol. 2011;18(3):387–95.PubMedCrossRef Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, et al. Allergy and risk of glioma: a meta-analysis. Eur J Neurol. 2011;18(3):387–95.PubMedCrossRef
37.
Zurück zum Zitat Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544–50.PubMedCrossRef Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544–50.PubMedCrossRef
38.
Zurück zum Zitat Ruan Z, Zhao Y, Yan L, Chen H, Fan W, Chen J, et al. Single nucleotide polymorphisms in IL-4Ra, IL-13 and STAT6 genes occurs in brain glioma. Front Biosci (Elite Ed). 2011;3:33–45.CrossRef Ruan Z, Zhao Y, Yan L, Chen H, Fan W, Chen J, et al. Single nucleotide polymorphisms in IL-4Ra, IL-13 and STAT6 genes occurs in brain glioma. Front Biosci (Elite Ed). 2011;3:33–45.CrossRef
39.
Zurück zum Zitat Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005;65(14):6459–65.PubMedCentralPubMedCrossRef Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, et al. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005;65(14):6459–65.PubMedCentralPubMedCrossRef
Metadaten
Titel
Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects
verfasst von
Hongyu Zhao
Weisong Cai
Shitao Su
Debao Zhi
Jie Lu
Shuo Liu
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1514-4

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.